Drugs Made In America Acquisition II Corp. (DMII) is a special purpose acquisition company formed in 2024 and publicly listed in 2025, focused on acquiring and consolidating pharmaceutical businesses to reshore drug manufacturing in the United States. With $500 million raised in its IPO and held in trust, DMII currently operates as a shell company with no revenues or operations. Its strategic vision targets integrated domestic pharmaceutical production using advanced manufacturing and AI technologies to mitigate critical drug shortages. Governance issues led to leadership changes in early 2026, while intense competition and regulatory complexities pose significant execution risks. Returns depend entirely on the successful completion and performance of an initial business combination within the two-year deadline.